Clinical Pharmacogenomics of Antidepressant Response
Phase 4 Clinical Pharmacogenomics of Antidepressant Response
2 other identifiers
observational
402
1 country
4
Brief Summary
The purpose of this study is to understand how genetic polymorphisms influence the efficacy and side effect profiles of Paroxetine and Escitalopram for major depression treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2006
Longer than P75 for all trials
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2006
CompletedFirst Submitted
Initial submission to the registry
October 3, 2006
CompletedFirst Posted
Study publicly available on registry
October 4, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2010
CompletedFebruary 1, 2010
January 1, 2010
4 years
October 3, 2006
January 29, 2010
Conditions
Keywords
Interventions
Eligibility Criteria
depressive patients in Taiwan
You may qualify if:
- self-identified as of Taiwanese/Chinese ethnic background, and report that both of their parents and all four or three of their grandparents are members of the same ethnic group;
- HAMD-21 \> 17 plus MDE (i.e., current major depressive episode) based on SCID;
- male or female, who, if of child-bearing potential, agrees to use effective contraception including the regular use of contraceptive pills, intra-uterine devises or abstinence;
- age \>= 18;
- capable of giving informed consent;
You may not qualify if:
- diagnosis of schizophrenia, schizophreniform disorder, schizoaffective disorder, schizotypal disorder, psychotic depression, bipolar disorders;
- current drug or alcohol abuse or dependence or history of drug or alcohol abuse or dependence within the past 6 months;
- unstable medical or neurological conditions that are likely to interfere with the treatment of depression;
- history of allergy to antidepressants;
- history of seizure disorder;
- pregnancy;
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- National Health Research Institutes, Taiwanlead
- National Science and Technology Council, Taiwancollaborator
- Chang Gung Memorial Hospitalcollaborator
- Taipei Medical University WanFang Hospitalcollaborator
- Taipei City Hospitalcollaborator
- Mackay Memorial Hospitalcollaborator
Study Sites (4)
Song-De Branch, Taipei City Hospital
Taipei, Taipei, 11000, Taiwan
Municipal Wan Fang Hospital
Taipei, Taipei, 11600, Taiwan
Mackay Memorial Hospital
Taipei, Taipei, 25115, Taiwan
Chang Gung Memorial Hospital
Taoyuan District, Taoyuan, 33305, Taiwan
Related Publications (1)
Tsai MH, Lin KM, Hsiao MC, Shen WW, Lu ML, Tang HS, Fang CK, Wu CS, Lu SC, Liu SC, Chen CY, Liu YL. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Pharmacogenomics. 2010 Apr;11(4):537-46. doi: 10.2217/pgs.09.168.
PMID: 20350136DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Keh-Ming Lin, MD, MPH
National Health Research Institutes, Taiwan
- PRINCIPAL INVESTIGATOR
Chia-Hui Chen, MD
National Health Research Institutes, Taiwan
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
October 3, 2006
First Posted
October 4, 2006
Study Start
January 1, 2006
Primary Completion
January 1, 2010
Study Completion
January 1, 2010
Last Updated
February 1, 2010
Record last verified: 2010-01